Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 5
Tirzepatide and MASLD in Mice
A mouse and cell study linked tirzepatide with less liver fat and inflammation, with Dectin-1 signaling proposed as part of the mechanism.
Tirzepatide Safety Signals in FAERS
A 2026 review found lower kidney-injury reporting and no significant suicidality signal for tirzepatide, with major FAERS limits.
GLP-1 Drugs and Neuroinflammation
A 2026 review links GLP-1 drugs to immune pathways in the brain, but human trials have not established a general neurological benefit.
GLP-1 safety cohort: what it found
A 2026 South Korean cohort linked semaglutide and liraglutide initiation with selected safety outcomes, without proving causation.
Personalising Tirzepatide Maintenance
A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.
Semaglutide in One BBS10 Case
One woman with BBS10-related Bardet-Biedl syndrome had improved metabolic markers over six months, but a case report cannot prove efficacy.
Semaglutide equity model explained
A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.
STRIDE: Semaglutide and PAD Walking
STRIDE found that semaglutide improved walking capacity in adults with type 2 diabetes and symptomatic peripheral artery disease.
Tirzepatide During ECT: One Case
One patient taking tirzepatide completed 17 ECT sessions without complications, but the case report cannot establish a safe protocol.
Tirzepatide and Migraine: Two Cases
Two patients reported fewer migraine days on tirzepatide, but weight loss and an uncontrolled design prevent causal conclusions.
Tirzepatide Ocular Study: What We Know
A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.
Vutiglabridin and Semaglutide in Mice
A preclinical mouse study found more fat loss with vutiglabridin plus semaglutide, but it provides no evidence of human efficacy.